Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin

Phase 1

Completed

Conditions: Drug-drug Interaction

Interventions: Drug: Tucatinib
Drug: Metformin
Drug: Iohexol

First Posted Date: 2019-02-01

Last Posted Date: 2019-03-27

Lead Sponsor: Seagen Inc.

Target Recruit Count: 18

Registration Number: NCT03826602

Locations: 🇺🇸
Pharmaceutical Research Associates, Salt Lake City, Utah, United States

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: Tisotumab Vedotin
Drug: Bevacizumab
Drug: Pembrolizumab
Drug: Carboplatin

First Posted Date: 2018-12-24

Last Posted Date: 2025-06-10

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 214

Registration Number: NCT03786081

Locations: 🇺🇸
Arizona Oncology Associates, Phoenix, Arizona, United States
🇺🇸
Univ California, Irvine Medical Center, Orange, California, United States
🇺🇸
Olive View - UCLA Research and Education Institute, Sylmar, California, United States

and more 64 locations

Effects of Tucatinib on Cardiac Repolarization in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tucatinib
Drug: placebo
Drug: moxifloxacin

First Posted Date: 2018-12-17

Last Posted Date: 2019-04-12

Lead Sponsor: Seagen Inc.

Target Recruit Count: 55

Registration Number: NCT03777761

Locations: 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

Phase 1

Completed

Conditions: Drug-drug Interaction

Interventions: Drug: tucatinib
Drug: repaglinide
Drug: itraconazole
Drug: rifampin
Drug: gemfibrozil
Drug: digoxin
Drug: tolbutamide
Drug: midazolam

First Posted Date: 2018-10-29

Last Posted Date: 2019-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 116

Registration Number: NCT03723395

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Tucatinib

First Posted Date: 2018-10-29

Last Posted Date: 2019-05-20

Lead Sponsor: Seagen Inc.

Target Recruit Count: 37

Registration Number: NCT03722823

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
NOCCR Knoxville and Volunteer Research Group, Knoxville, Tennessee, United States

and more 1 locations

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: tisotumab vedotin

First Posted Date: 2018-09-04

Last Posted Date: 2023-05-06

Lead Sponsor: Seagen Inc.

Target Recruit Count: 98

Registration Number: NCT03657043

Locations: 🇺🇸
Stanford Cancer Center South Bay, San Jose, California, United States
🇺🇸
Poudre Valley Health System (PVHS), Fort Collins, Colorado, United States
🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States

and more 34 locations

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: doxorubicin
Drug: vinblastine
Drug: dacarbazine
Drug: nivolumab
Drug: G-CSF

First Posted Date: 2018-08-24

Last Posted Date: 2024-11-05

Lead Sponsor: Seagen Inc.

Target Recruit Count: 255

Registration Number: NCT03646123

Locations: 🇺🇸
Los Angeles Cancer Network / Compassionate Care Research Group, Fountain Valley, California, United States
🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸
University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States

and more 73 locations

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: SEA-BCMA
Drug: dexamethasone
Drug: pomalidomide

First Posted Date: 2018-07-10

Last Posted Date: 2024-12-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 83

Registration Number: NCT03582033

Locations: 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸
Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 10 locations

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Phase 2

Active, not recruiting

Conditions: Colorectal Neoplasms
Exocrine Pancreatic Cancer
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: tisotumab vedotin
Drug: pembrolizumab
Drug: carboplatin
Drug: cisplatin

First Posted Date: 2018-04-02

Last Posted Date: 2025-06-19

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 348

Registration Number: NCT03485209

Locations: 🇺🇸
UC San Diego/Moores Cancer Center, La Jolla, California, United States
🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 141 locations

A Trial of Tisotumab Vedotin in Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: tisotumab vedotin

First Posted Date: 2018-02-19

Last Posted Date: 2023-07-25

Lead Sponsor: Seagen Inc.

Target Recruit Count: 102

Registration Number: NCT03438396

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Arizona Oncology Associate - Biltmore Cancer Center, Phoenix, Arizona, United States
🇺🇸
UCLA Dept. of OBGYN, Los Angeles, California, United States

and more 50 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy